Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 lot-to-lot consistency study of Prevnar 13 in healthy infants with routine pediatric vaccines
2008-003688-38Phase 3
- Sponsor
- Wyeth
- Start
- Apr 2015
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Prevnar 13 in pneumococcal disease (3 arms), sponsored by Wyeth. Primary endpoint: Geometric Mean Concentration for serotype-specific pneumococcal IgG antibody 1 month after the infant series.
02
Drugs
Prevnar 13
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2008-003688-38.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003688-38.